Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the ISGIO 2025 meeting focused on the rapidly changing treatment landscape for esophagogastric cancer, including the evolving use of immunotherapy for resectable disease, and the expanding landscape of targeted and immunological therapies for metastatic disease. These presentations were supplemented by a case discussion on optimizing the use of neoadjuvant therapy for a patient with resectable disease
Registration is
also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft
Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate novel data to effectively sequence available therapies for optimal outcomes in patients with GI cancers
- Apply best practices and evidence-based proactive strategies to monitor and manage treatment-related adverse events in patients receiving novel therapies and combination regimens
- Evaluate the latest efficacy and safety data for newly approved agents, novel combinations, and novel agents to consider their potential impact on evolving treatment paradigms in GI cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here